The US Federal Trade Commission (FTC) believes that an effective FOB approval pathway and laws preventing “pay-for-delay” deals are the only ways of reducing the cost of biologic drugs.
Demand for biopharmaceutical contract manufacturing will grow 16 per cent a year over the next five years, according to analysis by US market research group HighTech Business Decisions.
UK drug major GSK has had a busy week in the Asia, signing an influenza vaccine manufacturing deal with China’s Shenzhen Neptunus Interlong Bio-Technique just days after it opened a new S$600m (EUR294m) production facility in Singapore.
Commonwealth Biotechnologies (CBI) is set to acquire China-based peptide manufacturer GL Biochem, which it believes will create a dominant force in the non-GMP segment of the market.
Swedish CRO Syntagon has set up an office in Shanghai, China to forge stronger links with a broader range of local raw materials suppliers, saving its customers time and money.
CMO Kemwell is receiving technical assistance from Boehringer Ingelheim for the construction of its new biotech facility, which is designed to marry European technology with Indian low cost manufacturing.
MDS Pharma Services is renovating and expanding its Taiwanese discovery pharmacology operation in response to growing global demand for work performed in Asia.
JAPM and SABEQ have launched initiatives to help companies in Jordan bring their pharma packaging and manufacturing practices inline with established markets.
GE Healthcare hopes its new modular validation platform (MVP) will change the way drugmakers think about how they create new plants and bring existing manufacturing facilities up to code.
SAFC is seeking to improve its large-scale supply of pharma raw materials through a partnership with Cherokee Pharmaceuticals, which will use its expertise to ensure the products meet cGMP standards.
German glass making giant Gerresheimer has opened a new packaging plant in Danyang, China, further indicating its plans to grow in the world’s fifth largest pharmaceutical market.
PRA International has opened a drug safety centre in São Paulo, Brazil, expanding its presence in Latin America and bringing its array of services to a new market.
Power outages cost India $9.2bn (€6.5bn) in 2008, according to a report, with the disruptions causing direct losses in numerous sectors, including pharma and biotech.
US Patient recruitment specialist BBK Worldwide has set up a unit in Osaka, Japan to improve enrolment rates for studies in the country and help local pharma and biotech firms cut costs.
Stiffer penalties for counterfeiters could be counterproductive in less developed countries (LDC) and “entrench the corrupt symbiotic relationship between counterfeiters, lawmakers and officials”, according to a report
Singapore’s prudent spending means it can view the economic crisis as an opportunity, according to an executive director of its EDB, using saved funds to progress beyond its struggling rivals.
in-Pharmatechnologist's Nick Taylor looks back on BIO 2009, an event at which uncertainty about the development of the biotechnology industry’s future shape dominated proceedings.
HEM Pierre Vimont, Ambassador of France to the US, was at BIO 2009 talking about the measures his nation have taken to attract biotechs, including the introduction of the "most favourable R&D tax in Europe".
Fine chemicals firm Minakem believes that manufacturing capacity added by its newly acquired API plant in Dunkirk, France will reduce costs and help it compete on a global scale.
WuXi PharmaTech’s operating income fell by 25 per cent in Q1, in part because of an 81 per cent drop in revenues from manufacturing, but the company reconfirmed its 2009 financial guidance.
The increasingly global clinical trial sector demands more effective ethical and regulatory scrutiny according to a study published in the latest edition of the New England Journal of Medicine (NEJM).
US drug firms’ qualification of overseas API vendors will be subject to increased FDA scrutiny in the coming years according to a new industry report by analysts Hogan & Hartson (H&H).
CRO Eurotrials has brought in US business consultant AmeriStart to publicise and sell its trial services to pharmaceutical and biotech firms in North America.
French drug major Sanofi Aventis has unveiled plans for a €200m ($268m) biotechnology investment at its manufacturing facility in Vitry-sur-Seine near Paris, under its collaborative Biolaunch project.
Pharmafreight and Kryotrans have teamed up to offer a one-way, temperature-controlled shipping service that they claim will help pharmaceutical exporters cut costs and boost efficiency.
Greek authorities have banned the export of the anti-virals Relenza and Tamiflu to prevent the country’s stockpile being sold off through parallel trade as global demand for the drugs increases on concerns about a H1N1 influenza pandemic.
Two recombinant human albumins made by Novozymes' biopharma division have become the first to comply with the USP-NF's recently revised excipient monograph.
Pfizer is monitoring opportunities in follow-on biologics and continuing to look for small to mid-sized deals as it plans for life without Lipitor, global revenues of which fell by 13 per cent in Q1.
Novozymes Biopharma is building a new Bacillus-based hyaluronic acid (bHA) production facility in China to meet “increasing demand” for the substance that has drug delivery applications.
Novartis, Roche, GSK and Sanofi Pasteur are poised to start the months of work required to make a vaccine for the swine flu virus that, according to an AFP interview with Health Minister Jose Angel Cordova, is linked to 103 deaths in Mexico.
German CRO Clinicalprojects International (CPI) will begin providing its customers with the TrialMaster EDC solution though a deal with developer OmniComm.
Construction of a new stem cell research and processing plant began yesterday in China’s Eastern Jiangsu province as part of a joint project between the Chinese government and Shenzen Beike Biotechnology.
API maker Hovione’s manufacturing facility in Cork, Ireland was unveiled at an opening ceremony yesterday just two weeks after the previous owner, global drug giant Pfizer, formally handed over the keys.
Sinobiopharma is seeking a Chinese patent covering the manufacture of capsule forms of the heart drug perindopril, claiming it is the first company in the world to produce the medication in this easy to swallow format.
US clinical trials firm ChemDiv has bought Russian CRO Prudentas, boosting its presence in the country at a time when the treatment naïve populations in Eastern Europe are increasingly catching the eye of the global pharma and biotech industries.
Domino Printing is expanding its presence in Portugal through the €7m ($9m) acquisition of Labeljet SA and its subsidiary Marque TDI, which is currently a distributor for the traceability specialist.
Finding appropriate subjects in the booming trials market is a major stumbling block for drug firms and CROs, according to a new study by US market analysts Cutting Edge Information
Companies seeking research services in India and China will now be able to use a single contact following an alliance between GVK BIO and Excel, which the companies claim is the first to span the two nations.
Although the downturn has slowed Big Pharma’s investment in China, the country’s wide ranging healthcare reforms and changing economic landscape still provide considerable opportunities says PricewaterhouseCoopers (PwC).
Massachusetts Biotechnology Council’s (MBC) 2015 strategic plan has outlined the difficulties the state faces in attracting biomanufacturing and called for increased focus on R&D.
Pfizer is the latest company to seek greater control of its Indian subsidiary, falling into step with Swiss drug major Novartis which made a similar move late last month.
The US contract manufacturing sector is strong enough to bounce back from any short-term slow down caused by the credit crisis, according to a new report by Frost & Sullivan (F&S).
Cincinnati, US site management organisation (SMO) Radiant Research says that growing industry demand for trials outside the US is the key motivation for the link up with India’s Spectrum Clinical Research.
The new chairman of US trade body the Pharmaceutical Research and Manufacturers of America (PhRMA) – AstraZeneca CEO David Brennan – has laid out his vision for reforming the “broken” healthcare system.
PTI Packaging Systems chose this year's Interphex show to introduce its new unit dose, or "stick pack," production machine to the North American packaging sector.
Tom Beil, SAFC’s VP of Quality and Regulatory affairs, whose talk on fine chemicals supply was a highlight of last month's DCAT week, spoke with in-PharmaTechnologist about the benefits and risks of working with global suppliers.
